| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
49,160,000 |
| Market
Cap: |
351.99(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.14 - $13.81 |
|
| Level
I Sector: |
Financials |
| Level
II Sector: |
Financial Services |
| Level
III Sector: |
Diversified Investments |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Co.'s primary product candidate, pemvidutide (proposed INN), is a good laboratory practices-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis. In addition, Co. is developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
300 |
31,500 |
| Total Buy Value |
$0 |
$0 |
$863 |
$138,033 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
6 |
| Total Shares Sold |
0 |
0 |
0 |
155,302 |
| Total Sell Value |
$0 |
$0 |
$0 |
$2,133,902 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
9 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shah Nimish P |
10% Owner |
– – • |
2020-05-26 |
4 |
B |
$8.79 |
$6,539,642 |
I/I |
700,000 |
2,396,364 |
1.5 |
62% |
|
| Velocity Pharmaceutical Holdings Llc |
10% Owner |
– – • |
2020-05-15 |
4 |
S |
$4.65 |
$142,392 |
D/D |
(30,622) |
1,687,250 |
|
-213% |
|
| Velocity Pharmaceutical Holdings Llc |
10% Owner |
– – • |
2020-05-14 |
4 |
S |
$4.81 |
$814,708 |
D/D |
(169,378) |
1,717,872 |
|
-191% |
|
| Garg Vipin K |
President and CEO |
• • – |
2020-04-30 |
4 |
D |
$3.05 |
$6,146 |
D/D |
(2,015) |
320,160 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2020-03-31 |
4 |
D |
$3.02 |
$6,088 |
D/D |
(2,016) |
322,175 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2020-02-29 |
4 |
D |
$3.70 |
$7,456 |
D/D |
(2,015) |
324,191 |
|
- |
|
| Brown William Michael |
Chief Financial Officer |
• – – |
2020-01-31 |
4 |
A |
$1.46 |
$11,769 |
D/D |
8,061 |
8,061 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2020-01-31 |
4 |
A |
$1.46 |
$16,482 |
D/D |
11,289 |
326,206 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2020-01-31 |
4 |
A |
$1.46 |
$5,399 |
D/D |
3,698 |
5,535 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2020-01-30 |
4 |
D |
$1.77 |
$3,567 |
D/D |
(2,015) |
314,917 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2019-12-30 |
4 |
D |
$1.80 |
$3,598 |
D/D |
(1,999) |
316,932 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2019-11-30 |
4 |
D |
$1.82 |
$43,636 |
D/D |
(23,976) |
318,931 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2019-09-05 |
4 |
B |
$2.10 |
$42,000 |
D/D |
20,000 |
342,907 |
2.81 |
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2018-11-30 |
4 |
A |
$0.00 |
$0 |
D/D |
322,907 |
322,907 |
|
- |
|
| Pisano Wayne |
Director |
– • – |
2018-10-09 |
4 |
B |
$4.59 |
$9,180 |
D/D |
2,000 |
2,000 |
2.39 |
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-09-12 |
4 |
A |
$0.00 |
$0 |
I/I |
2,069,993 |
8,345,145 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-07-11 |
4 |
A |
$0.00 |
$0 |
I/I |
663,346 |
6,275,152 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-06-15 |
4 |
A |
$0.00 |
$0 |
I/I |
14,449 |
5,611,806 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
I/I |
720,878 |
5,597,357 |
|
- |
|
| Enright William |
President and CEO |
• • – |
2018-05-25 |
4 |
B |
$0.51 |
$660 |
D/D |
1,300 |
365,839 |
2.73 |
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2018-05-21 |
4 |
OE |
$0.08 |
$4,410 |
D/D |
55,120 |
55,120 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-05-16 |
4 |
A |
$0.00 |
$0 |
I/I |
767,728 |
4,876,479 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-05-15 |
4 |
A |
$0.00 |
$0 |
I/I |
274,703 |
4,108,751 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-04-16 |
4 |
A |
$0.00 |
$0 |
I/I |
700,066 |
3,834,048 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-03-15 |
4 |
A |
$0.00 |
$0 |
I/I |
261,969 |
3,133,982 |
|
- |
|
417 Records found
|
|
Page 7 of 17 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.11 (1.51%) 
